{"disease":{"id":"uc-urothelial-cancer","name":"uc urothelial cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02872714","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02903914","title":"Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02318277","title":"A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02646748","title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07155044","title":"A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT03361865","title":"Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04152018","title":"Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03374488","title":"Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}